Following extraordinary growth in 2020 and 2021, the life science group Sartorius again outperformed the market in fiscal 2022, achieving its targets for sales revenue and profitability. Both divisions contributed to this development and, according to preliminary figures, recorded double-di ... more
Sartorius completes acquisition of Novasep’s chromatography division
Sales revenue forecast for 2022 updated due to acquisition
Sartorius announced that, through its subgroup Sartorius Stedim Biotech, it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 employees work at the Pompey site in eastern France and some in the USA, China, and India.
The portfolio acquired comprises chromatography systems primarily suited for smaller biomolecules, such as oligonucleotides, peptides, and insulin, as well as innovative systems for continuous manufacturing of biologics. Since 2018, Novasep and Sartorius have also been jointly developing optimized systems for a membrane-based chromatography technology.
As the acquisition is expected to generate additional non-organic sales revenue growth of around 1 percentage point in 2022, Sartorius has updated its sales revenue forecast for the current year as follows: Consolidated sales revenue is now expected to increase by about 15 percent to 19 percent (previously about 14 percent to 18 percent), with non-organic growth from acquisitions projected to contribute about 2 percentage points (previously about 1 percentage point). The company’s underlying EBITDA margin remains forecasted at about 34 percent this year.
For the Bioprocess Solutions Division, the company now forecasts sales revenue growth of about 17 percent to 21 percent for 2022 (previously about 16 percent to 20 percent), with non-organic growth from acquisitions contributing around 2 percentage points (previously around 1 percentage point). The division’s underlying EBITDA margin is still expected to be around 36 percent. The 2022 forecasts for the Lab Products & Services Division remain unchanged: Accordingly, the company continues to project sales revenue growth of about 6 percent to 10 percent, including a non-organic growth contribution from acquisitions of around 1 percentage point, and an underlying EBITDA margin of around 26 percent for the division.
All forecasts are based on constant currencies.
Sartorius closed the first nine months of 2022 in both divisions with double-digit sales revenue and earnings growth and specified its outlook for the current fiscal year. “In the first nine months, Sartorius achieved significant growth in a challenging environment. Both divisions recorded ... more
Sartorius recorded a dynamic start to fiscal 2022, with sales revenue and earnings posting strong double-digit growth rates in the first quarter compared with the prior-year period. Based on its performance in the first three months, Sartorius confirms its outlook for fiscal 2022. “Sartoriu ... more
Rests lightly in your hand thanks to its ergonomically designed handle and finger hook ✓ Eases your workload and protects you from strain, even when you need to pipette for hours ✓ Quick and easy to clean and can also be steam-sterilized or autoclaved as-is, without disassembly ✓ more
Biolayer interferometer system ✓ 8-channel measurement ✓ Active temperature control ✓ Protein-protein interaction assay ✓ Fully automated ✓ GxP compliant ✓ more
Biolayer interferometer system ✓ Minimal space required ✓ Only 4 µL of sample ✓ Protein quantification ✓ Protein kinetics ✓ Protein-protein interactions ✓ more
Novasep announces it has strengthened its position in the fine chemicals marketplace with the appointment of Udo Steinhauer as fine chemicals market director within the synthesis business unit of Novasep. Udo Steinhauer has a strong industrial experience gained over 18 years in diverse mana ... more
Novasep announced an investment of EUR 30 million to build in Europe what will be the world's largest chromatography plant used for the production of a large volume commercial API (active pharmaceutical ingredient).The plant will be built on Novasep's existing Mourenx site in France and wil ... more
Novasep and instrAction announced that they have entered a strategic alliance. The alliance will offer customers in the life science industry a combination of instrAction’s proprietary API-selective stationary phases (Instruction® Receptor Phase) and Novasep purification capabilities and hi ... more
- 1Can the AI driving ChatGPT help to detect early signs of Alzheimer's disease?
- 2Simple nasal swab can provide early warning of emerging viruses
- 3Holes in T cells
- 4Molecular archeology: 1200-year-old DNA sequences from Madagascar lead to the discovery of an extinct tortoise
- 5Bruker Announces Acquisition of ACQUIFER Imaging GmbH
- 6How old is your brain, really?
- 7The architecture of shattered genomes
- 8Bayesian inference massively cuts time of X-ray fluorescence analysis!
- 9AI detects rare forms of dementia
- 10Texas A&M research aims to improve Lyme disease diagnostics